ArticleCancers2023
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia.Cell death & disease · 2026Article
- Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting.Blood advances · 2026Article
- Metabolic Signature ofJournal of personalized medicine · 2025Review
- Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review.Cancers · 2025Review
- Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia.Current pharmacology reports · 2024Article
- Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024Review
- DPEP Inhibits Cancer Cell Glucose Uptake, Glycolysis and Survival by Upregulating Tumor Suppressor TXNIP.Cells · 2024Article
- Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.Cancers · 2024Review
- A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Alexandra McLean StevensDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Eric S SchaferDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Minhua LiDevelopment, Disease Models & Therapeutics Graduate Program, Baylor College of Medicine, Houston, TX 77030, USA.
Maci TerrellDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Raushan RashidDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Hana PaekDepartment of Pharmacy, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Melanie B BernhardtDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0002-9612-3624
Allison WeisnichtDepartment of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Wesley T SmithDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Noah J KeoghDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Michelle C AlozieDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Hailey H OviedoDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Alan K GonzalezDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Tamilini IlangovanDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Alicia Mangubat-MedinaDepartment of Chemistry, Rice University, Houston, TX 77005, USA.
Haopei WangDepartment of Chemistry, Rice University, Houston, TX 77005, USA.
Eunji JoDuncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Cara A RabikThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Claire BocchiniDepartment of Pediatric Infectious Diseases, Baylor College of Medicine, Houston, TX 77030, USA.
Susan HilsenbeckDuncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Zachary T BallDepartment of Chemistry, Rice University, Houston, TX 77005, USA.ORCID 0000-0002-8681-0789
Todd M CooperCancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA 98105, USA.
Michele S RedellDepartment of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Baylor College of Medicine · USRice University · USJohns Hopkins University · USSeattle Children's Hospital · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9MUM1HG006348: Cas9 Genome Integrity Supplemental ProposalUM1HG006348 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI Jason D. Heaney, Chih-Wei Logan Hsu · 2016 to 2026
$47.5MVirology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI RICE, ANDREW P · 1994 to 2015
$21.7MMETABOLIC IMPACTS OF TYPE II INTERFERON SIGNALS IN OBESITYR01DK114356 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI HARTIG, SEAN · 2017 to 2025
$4.6MBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kCure Childhood Cancer, Turn it Gold, Robert A. Welch Foundation Research Grant C-1680 no grant numbersNCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NHGRI NIH HHS UM1 HG006348NIAID NIH HHS P30 AI036211NIDDK NIH HHS R01 DK114356
Abstract
Survival of pediatric AML remains poor despite maximized myelosuppressive therapy. The
Indexed as
metabolismoxidative phosphorylationoxygen consumption ratepatient-derivedpediatricpneumocystis jiroveci pneumoniaxenograft
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.